Responses
Clinical/translational cancer immunotherapy
Original research
Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung
Compose a Response to This Article
Other responses
No responses have been published for this article.